Please assess the completion status of the following clinical trial:

Trial Title: Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Accessible volume and quality of tumor tissue for vaccine production~* MRI after surgery with minimal tumor remnant.~* Between 18 and 70 years of age.~* Must have histologically confirmed glioma grade IV, and a candidate for combined radiation therapy and chemotherapy (Stupps regimen).~* Must be ambulatory with a ECOG performance status 0 or 1.~* A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and beginning of vaccination.~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented.~Exclusion Criteria:~* Tumor in a localization where a modest increase in size due to reactive oedema may have a large impact on patients neurological condition.~* Large tumor remnant after surgery.~* History of prior malignancy other than glioma, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB.~* Chronic active infection requiring antibiotic therapy.~* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.~* Prior splenectomy.~* Glucocorticoid treatment not possible to terminate due to autoimmune disease or increased intracranial pressure.~* Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.~* History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.~* Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination.~* Pregnancy or lactation.~* Any reason why, in the opinion of the investigator, the patient should not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).